Changzhou Qianhong Biopharma CO.,LTD (SHE:002550)

SHE:002550 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020
Cash & Equivalents	638.55	439.95	576.23	409.26	617.81	516.11
Short-Term Investments	-	192.9	64.95	-	-	-
Trading Asset Securities	203.6	273.83	71.98	67.48	68.23	234.28
Cash & Short-Term Investments	842.15	906.67	713.16	476.73	686.03	750.39
Cash Growth	14.30%	27.13%	49.59%	-30.51%	-8.58%	-13.35%
Accounts Receivable	342.06	274.25	275.52	632.87	447.67	461.88
Other Receivables	23.98	23.24	16.9	2.48	2.56	4.81
Receivables	366.04	297.48	292.42	635.35	450.23	466.69
Inventory	367.04	426.81	602.01	536.48	400.63	315.97
Prepaid Expenses	-	-	-	-	0.01	0.01
Other Current Assets	283.03	62.73	18.39	38.72	33.04	23.96
Total Current Assets	1,858	1,694	1,626	1,687	1,570	1,557
Property, Plant & Equipment	549.3	563.6	561.27	616.39	611.77	599.56
Long-Term Investments	114.99	160.08	203.22	156.78	40.56	6.71
Goodwill	11.14	11.14	11.14	11.14	11.14	11.14
Other Intangible Assets	108.7	109.32	113.14	100.86	106.92	114.42
Long-Term Deferred Tax Assets	66.42	75.26	90.53	101.49	99.42	105.52
Long-Term Deferred Charges	143.85	138.04	93.77	60.33	46.85	38.14
Other Long-Term Assets	95.64	79.31	67.05	71.67	21.81	19.27
Total Assets	2,948	2,830	2,766	2,806	2,508	2,452
Accounts Payable	74.41	88.64	41.18	45.97	71.23	106.25
Accrued Expenses	14.67	88.06	89.7	101.94	99.55	96.63
Short-Term Debt	20.02	21.49	56.31	103.05	93.56	41.85
Current Income Taxes Payable	13.7	1.53	0.64	0.05	-	15.02
Current Unearned Revenue	2.34	9.68	9.71	15.58	19.67	11.86
Other Current Liabilities	56.68	14	8.28	11.63	12.34	19.38
Total Current Liabilities	181.83	223.39	205.81	278.22	296.35	290.98
Long-Term Unearned Revenue	88.21	86.46	81.85	89.35	93.42	94.87
Long-Term Deferred Tax Liabilities	3.99	4.02	4.52	4.96	0.47	0.5
Total Liabilities	274.03	313.87	292.17	372.53	390.24	386.35
Common Stock	1,280	1,280	1,280	1,280	1,280	1,280
Additional Paid-In Capital	41.65	41.65	41.65	36.29	29.38	25.58
Retained Earnings	1,530	1,369	1,163	1,134	960.89	929.79
Treasury Stock	-170.86	-170.86	-30.09	-	-145.05	-154.38
Comprehensive Income & Other	-2.32	-2.42	0.36	-0.06	2.23	-0.88
Total Common Equity	2,679	2,517	2,455	2,450	2,127	2,080
Minority Interest	-4.23	-0.87	18.98	-16.95	-9.09	-14.56
Shareholders' Equity	2,674	2,517	2,474	2,433	2,118	2,065
Total Liabilities & Equity	2,948	2,830	2,766	2,806	2,508	2,452
Total Debt	20.02	21.49	56.31	103.05	93.56	41.85
Net Cash (Debt)	822.13	885.19	656.85	373.69	592.48	708.54
Net Cash Growth	20.80%	34.76%	75.78%	-36.93%	-16.38%	35.81%
Net Cash Per Share	0.65	0.70	0.51	0.29	0.49	0.59
Filing Date Shares Outstanding	1,250	1,250	1,275	1,280	1,280	1,280
Total Common Shares Outstanding	1,250	1,250	1,275	1,280	1,280	1,280
Working Capital	1,676	1,470	1,420	1,409	1,274	1,266
Book Value Per Share	2.14	2.01	1.93	1.91	1.66	1.63
Tangible Book Value	2,559	2,397	2,331	2,338	2,009	1,954
Tangible Book Value Per Share	2.05	1.92	1.83	1.83	1.57	1.53
Buildings	-	498.75	498.75	525.73	524.28	448.65
Machinery	-	568.44	558.3	504.84	461.29	426.63
Construction In Progress	-	61.25	8.19	54.1	39.24	76.54

Source: S&P Global Market Intelligence. Standard template. Financial Sources.